Papel de los estimulantes de eritropoyesis en la anemia neonatal
Resumen
La anemia es una patología comúnmente encontrada en la población neonatal; es secundaria a una serie de factores de riesgo fisiológicos y no fisiológicos que contribuyen a su desarrollo. Entre sus variantes se encuentra la enfermedad hemolítica del feto y el recién nacido, la cual es considerada la causa más frecuente de anemia en dicha población. Se realizó la revisión bibliográfica en las bases de datos Medline, Science Direct y Lilacs hasta agosto de 2020. En la búsqueda y selección de los artículos se usaron los términos MeSH: anemia neonatal, eritroblastosis fetal y eritropoyetina. Para el tratamiento de dicha patología se dispone de a transfusión de glóbulos rojos y los agentes estimulantes de la eritropoyesis; el uso de eritropoyetina humana recombinante como parte del tratamiento ha sido ampliamente discutido y controvertido, no bstante, hay estudios que demuestran que su uso reduce la necesidad de transfusiones sanguíneas.
Descargas
Disciplinas:
Pediatría, HematologíaReferencias bibliográficas
Colombatti R, Sainati L, Travisanuto D. Anemia and transfusion in the neonate. Semin fetal neonat m. 2016;21(1): 2-9 Doi: 10.1016/j.siny.2015.12.001
Pavo García M. R, Muñoz Díaz M., Baro Fernández M. Anemia en la edad pediátrica. Form Act Pediatr Aten Prim. 2016;9(4):149-55
Mamoury, G., Hamedy, A., Akhlaghi, F. Cord Hemoglobin in Newborns in Correlation with Maternal Hemoglobin in Northeastern Iran. Iranian Journal of Medical Sciences, 2015; 28(4): 166-168
Peña A, Urrutia ML, Vera GH. Anemia neonatal por transfusión feto-materna: reporte de un caso. Rev Mex Pediatr. 2014;81(6):218-221
Bonastre-Blanco E, Thió-Lluch M, Monfort-Carretero L. Anemia neonatal. An. de Pediatria Contin. 2010; 8(2): 73-80. Doi: 10.1016/S1696-2818(10)70013-5
Da Costa L. Anémies hémolytiques du nouveau-né. EMC (Elsevier Masson SAS, Paris), Pédiatrie, 4-002-R-40, 011
Provan D, Baglin T, Dokal I. Vos J. Hematología pediátrica. En: Pérez G. Manual de hematología clínica. Vol 4. España: Elsevier. 2017; p. 559-634
Li L, Huang L, Luo G, Luo Y, Fang Q. Prenatal treatment of severe fetal hemolytic disease due to anti-M alloimmunization by serial intrauterine transfusions. Taiwan J Obstet Gynecol. 2017; 56(3):379-381. Doi:10.1016/j.tjog.2017.04.022
Markham KB, Rossi KQ, Nagaraja HN, O’Shaughnessy RW. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. Am J Obstet Gynecol. 2015;213(1):68.e1-68.e5. Doi:10.1016/j.ajog.2015.01.049
López-Catzín JF, Bolado-García PB, Gamboa-López GJ, et al. Disminución de transfusiones en prematuros con anemia tratados con Eritropoyetina. Rev Med Inst Mex Seguro Soc. 2016;54(5):576-580
Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. Cochrane Database Syst Rev. 2017 Nov 16;11(11):CD004863. Doi: 10.1002/14651858.CD004863.pub5
Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015; 2015:146-151. Doi:10.1182/asheducation-2015.1.146
Ohls RK, Christensen RD, Kamath-Rayne BD, Rosenberg A, Wiedmeier SE, Roohi M, et al. A Randomized, Masked, Placebo Controlled Study of Darbepoetin Alfa in Preterm Infants. PEDIATRICS 2013; 132(1): e119-e127
Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middleincome countries. Ann N Y Acad Sci. 2019; 1450(1): 15–31. Doi:10.1111/nyas.14092
Ifeanyi OE. Hemolytic disease of the newborn: a review. Inter. J. of Pharmacotherapy 2015; 5(1): 1-10
Ree IMC, Smits-Wintjens VEHJ, Van der Bom JG, Van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol 2017; 10(7): 607-616. Doi: 10.1080/17474086.2017.1331124
Esan AJ. Hemolytic Disorders of the Newborn, Current Methods of Diagnosis and Treatment: A Review Study. J Hematol Blood Transfus. 2016; 3: 1-18. Doi: 10.24966/HBTD-2999/100008
Li S, Mo C, Huang L, et al. Hemolytic disease of the fetus and newborn due to alloanti-M: three Chinese case reports and a review of the literature. Transfusion. 2019;59(1):385-395. Doi:10.1111/trf.15054
Mawson AR, Croft AM. Rubella Virus Infection, the Congenital Rubella Syndrome, and the Link to Autism. Int. J. Environ. Res. Public Health 2019: 16: 1-28. Doi:10.3390/ijerph16193543
Wang L, Liu H. Pathogenesis of aplastic anemia. Hematology. 2019;24(1):559-566. Doi:10.1080/16078454.2019.1642548
Lotero V. Anemia en niños Deficiencia de hierro. Fundación Valle de Lili. 2010;(165)
Acuña C, Cuero K, Espitia K, Rojas R, Torres R. Anemia drepanocítica y situación en Colombia: Revisión. Bio. 2018;1(3)
Lokeshwar MR, Dalal R, Manglani M, Shah N. Anemia in newborn. Indian J Pediatr. 1998;65(5):651-61. Doi: 10.1007/BF02731037
Aher S, Malwatkar K, Kadam S. Neonatal anemia. Semin Fetal Neonatal Med. 2008 Aug;13(4):239-47. Doi: 10.1016/j.siny.2008.02.009
Kett JC. Anemia in infancy. Pediatr Rev. 2012 Apr;33(4):186-7. Doi: 10.1542/pir.33-4-186
Oski FA, Brugnara C, Nathan DG. Un abordaje diagnóstico del paciente anémico. En: Hematología de la infancia y la niñez de Nathan y Oski, 6th, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Filadelfia 2003. p.409
Bhutani VK, Zipursky A, Blencowe H, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res. 2013;74 :86-100. Doi:10.1038/pr.2013.208
Hendrickson JE, Delaney M. Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations. Transfus Med Rev. 2016;30(4):159-164. Doi: 10.1016/j.tmrv.2016.05.008
Fikac L. Neonatal Blood Loss Risks. Crit Care Nurs Q. 2019;42(2):202-204. DOI: 10.1097/CNQ.0000000000000255
Cavlovich FE. Subgaleal hemorrhage in the neonate. J Obstet Gynecol Neonatal Nurs. 1995;24(5):397-404. Doi: 10.1111/j.1552-6909.1995.tb02496.x
Akin MA, Coban D, Doganay S, Durak Z, Kurtoglu S. Intrahepatic and adrenal hemorrhage as a rare cause of neonatal anemia. J Perinat Med. 2011; 39(3):353-4. Doi: 10.1515/jpm.2011.018
Saroha V, Josephson CD, Patel RM. Epidemiology of Necrotizing Enterocolitis: New Considerations Regarding the Influence of Red Blood Cell Transfusions and Anemia. Clin Perinatol. 2019 Mar;46(1):101-117. Doi: 10.1016/j.clp.2018.09.006
Carroll PD, Widness JA. Nonpharmacological, blood conservation techniques for preventing neonatal anemia-effective and promising strategies for reducing transfusion. Semin Perinatol. 2012;36(4):232-43. Doi: 10.1053/j.semperi.2012.04.003
Sijó A, Saurez G, Velázquez D, Méndez L, Alfonso A, Vargas. Eficacia y seguridad de la eritropoyetina en la anemia de la prematuridad. Rev Cubana Hematol Inmunol Hemoter. 2013;85(2):202-12
Juul SE, Vu PT, Comstock BA, Wadhawan R, Mayock DE, Courtney SE, et al. Preterm Erythropoietin Neuroprotection Trial Consortium. Effect of HighDose Erythropoietin on Blood Transfusions in Extremely Low Gestational Age Neonates: Post Hoc Analysis of a Randomized Clinical Trial. JAMA Pediatr. 2020;174(10):933-943. Doi: 10.1001/jamapediatrics.2020.2271
Vu PT, Ohls RK, Mayock DE, German KR, Comstock BA, Heagerty PJ, Juul SE; PENUT Consortium. Transfusions and neurodevelopmental outcomes in extremely low gestation neonates enrolled in the PENUT Trial: a randomized clinical trial. Pediatr Res. 2021:1–8. Doi: 10.1038/s41390-020-01273-w
Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol. 1999;6(6):420-6. Doi: 10.1097/00062752-199911000-00012
Aher SM, Ohlsson A. Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. Cochrane Database Syst Rev. 2019;2(2):CD004868. Doi: 10.1002/14651858.CD004868.pub5
Cabrera García L, Ruiz Antorán B, Sancho López A. Eritropoyetina: revisión de sus indicaciones. Inf Ter Sist Nac Salud 2009; 33:3-9
Figueras J. Eritropoyetina en neonatología. An Pediatr (Barc). 2010;73(6):301–04
Neelakantan S, Widness JA, Schmidt RL, Veng-Pedersen P. Erythropoietin pharmacokinetic/pharmacodynamicanalysis suggests higher doses in treating neonatal anemia. Pediatr Int. 009;51(1):25-32. Doi: 10.1111/j.1442-200X.2008.02648.x
E. Álvarez E, Pérez JM Figueras J, Estrany C. Tratamiento con eritropoyetina para la anemia tardía tras enfermedad hemolítica del recién nacido. An Pediatr (Barc). 2010; 73(6):334–339
Zuppa AA, Alighieri G, Fracchiolla A, Catenazzi P, D’Antuono A, Riccardi R, Cavani M, Romagnoli1 C. Confronto tra due protocolli con Eritropoietina Umana Ricombinante (rHuEpo) nel trattamento dell’anemia tardiva nei neonati con Isoimmunizzazione Rh. Ped. Med. Chir. (Med. Surg. Ped.). 2012, 34: 186-191
El-Lahony DM, Saleh NY, Habib MS, Shehata MA, El-Hawy MA. The role of recombinant Human erythropoietin in neonatal anemia. Hematol Oncol Stem Cell 2019. Doi: 10.1016/j.hemonc.2019.08.004
Kandasamy Y, Kumar P, Hartley L. The effect of erythropoietin on the severity of retinopathy of prematurity. Eye (Lond). 2014; 28(7):814-8. Doi: 10.1038/eye.2014.95
Rangarajan V, Juul SE. Erythropoietin: Emerging Role of Erythropoietin in Neonatal Neuroprotection. Pediatric Neurology 51. 2014. 481- 488
Ree IMC, Lopriore E. Updates in Neonatal Hematology: Causes, Risk Factors, and Management of Anemia and Thrombocytopenia. Hematol Oncol Clin North Am. 2019;33(3):521-532. Doi: 10.1016/j.hoc.2019.01.013
Widness JA. Pathophysiology of Anemia During the Neonatal Period, Including Anemia of Prematurity. Neoreviews. 2008; 9(11): e520. Doi:10.1542/neo.9-11-e520
Lokeshwar MR, Dalal R, Manglani M, Shah N. Anemia in newborn. Indian J Pediatr. 1998;65(5):651-661. Doi:10.1007/BF02731037
Lubetzky R, Ben-Shaceras S, Mimani F, Dollberg S. Mode of delivery and neonatal hematocrit. Am J Perinatol. 2000;17(3):163-65
Mesquita M, Iramain R, Troche Z. Anemia neonatal dentro de las 24 horas de vida: prevalencia y factores perinatales asociados. Pediatr. (Asunción). 2005;32(1):10-15
Letterio J, Pateva I, Petrosiute A, Ahuja S. Hematologic and Oncologic Problems in the Fetus and Neonate. Fanaroff and Martin’s Neonatal-Perinatal Medicine. 2020; 79:1416-1475
Tutschek B, Hechexr L, Somville T, Bender H. Twin to twin transfusion syndrome complicated by spontaneous mid trimester uterine rupture. J Perinatal Med. 2004; 32(1):95-7
Johnsen S, Albrechtsen S, Pirhonen J. Twin to twin transfusion, treated with serial amniocenteses. Acta Obstet Gynecol Scand. 2004; 83(4):326-29
Cloherty J, Eichenwald E, Stark A, editores. Manual de cuidados neonatales. Barcelona: Masson; 2005
Zonnenberg IA, Vermeulen RJ, Rohaan MW, Van Weissenbruch MM, Groenendaal F, de Vries LS. Severe Neonatal Anaemia, MRI Findings and Neurodevelopmental Outcome. Neonatology. 2016; 109(4):282-288. Doi:10.1159/000443320
Rocha G, Pereira S, Antunes-Sarmento J, Flôr-de-Lima F, Soares H, Guimarães H. Early anemia and neonatal morbidity in extremely low birth-weight preterm infants. J Matern Fetal Neonatal Med. 2019; 1-7. Doi:10.1080/14767058.2019.1689948
Stefanovic V. Fetomaternal hemorrhage complicated pregnancy: risks, identification, and management. Curr Opin Obstet Gynecol. 2016; 28(2):86-94. Doi:10.1097/GCO.0000000000000248
Christensen RD, Lambert DK, Baer VL, et al. Severe neonatal anemia from fetomaternal hemorrhage: report from a multihospital health-care system. J Perinatol. 2013; 33(6):429-434. Doi:10.1038/jp.2012.142
Banerjee J, Asamoah FK, Singhvi D, Kwan AW, Morris JK, Aladangady N. Haemoglobin level at birth is associated with short term outcomes and mortality in preterm infants. BMC Med. 2015; 13:16. Doi:10.1186/s12916-014-0247-6
Brugnara C, Platt OS. The erythrocyte and its disorders. (7th ed.) S.H. Orkin, D.G. Nathan, D. Ginsburg, A.T. Look, D.E. Fisher, S.E. Lux (Eds.), Nathan and Oski’s hematology of infancy and childhood, vol. 1, Elsevier, Philadelphia. 2009: 36-66
Andersen CC, Collins CL. Poor circulation, early brain injury, and the potential role of red cell transfusion in premature newborns. Pediatrics. 2006;117(4):1464-1466. Doi:10.1542/peds.2005-3197
Sann C, Bourgeois J, Stephen A, Putet G. Outcome of 249 premature infants less than 29 weeks gestational age. Arch Pediatr. 2001; 8(3):250-58
.png)
